- Home
- MODD vs SCLX Comparison
MODD vs SCLX Comparison
Compare MODD & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MODD
- SCLX
- Stock Information
- Founded
- MODD 1998
- SCLX 2011
- Country
- MODD United States
- SCLX United States
- Employees
- MODD N/A
- SCLX N/A
- Industry
- MODD Industrial Specialties
- SCLX Biotechnology: Pharmaceutical Preparations
- Sector
- MODD Health Care
- SCLX Health Care
- Exchange
- MODD Nasdaq
- SCLX Nasdaq
- Market Cap
- MODD 39.0M
- SCLX 35.7M
- IPO Year
- MODD N/A
- SCLX N/A
- Fundamental
- Price
- MODD $0.67
- SCLX $17.70
- Analyst Decision
- MODD
- SCLX Strong Buy
- Analyst Count
- MODD 0
- SCLX 3
- Target Price
- MODD N/A
- SCLX $367.50
- AVG Volume (30 Days)
- MODD 1.4M
- SCLX 309.9K
- Earning Date
- MODD 11-13-2025
- SCLX 08-13-2025
- Dividend Yield
- MODD N/A
- SCLX N/A
- EPS Growth
- MODD N/A
- SCLX N/A
- EPS
- MODD N/A
- SCLX N/A
- Revenue
- MODD N/A
- SCLX $44,236,000.00
- Revenue This Year
- MODD N/A
- SCLX $89.26
- Revenue Next Year
- MODD N/A
- SCLX $203.95
- P/E Ratio
- MODD N/A
- SCLX N/A
- Revenue Growth
- MODD N/A
- SCLX N/A
- 52 Week Low
- MODD $0.63
- SCLX $3.60
- 52 Week High
- MODD $2.37
- SCLX $39.90
- Technical
- Relative Strength Index (RSI)
- MODD 36.53
- SCLX 42.76
- Support Level
- MODD $0.68
- SCLX $14.80
- Resistance Level
- MODD $0.72
- SCLX $19.41
- Average True Range (ATR)
- MODD 0.03
- SCLX 3.44
- MACD
- MODD -0.00
- SCLX -1.41
- Stochastic Oscillator
- MODD 0.00
- SCLX 15.54
About MODD Modular Medical Inc.
Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.